Simulations Plus

Simulations Plus LT Debt/Equity

Delisted·Oct 7, 2026

The Long-Term Debt to Equity Ratio of Simulations Plus (SLP) as of Nov 11, 2026 is 0.10. In the previous year, Long-Term Debt to Equity Ratio was 0.22 — a change of -53.03% (lower).

LT Debt/Equity

0.10

YoY

-53.03%

Last updated:

Long-Term Debt to Equity Ratio of Simulations Plus is 2018 0.10 . Long-Term Debt to Equity Ratio of Simulations Plus was 2017 0.22 . It decreases by -53.03% lower compared to the previous year.

The Simulations Plus LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2014
0.11 USD
Jan 1, 2015
0.05 USD
Jan 1, 2017
0.22 USD
Jan 1, 2018
0.10 USD
The Simulations Plus LT Debt/Equity history
YEARLT Debt/EquityYoY
0.10-53.03%
0.22+334.33%
0.05-54.84%
0.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

Long-Term Debt to Equity Ratio of Simulations Plus is 0.10 in 2018.

Long-Term Debt to Equity Ratio of Simulations Plus changed from 0.22 to 0.10, representing a -53.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Simulations Plus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Simulations Plus

All Key Metrics — Simulations Plus